<DOC>
	<DOCNO>NCT01554943</DOCNO>
	<brief_summary>Late Cardiac Evaluation Three Arm Belgian Trial A phase III randomize trial involve node-positive early breast cancer patient long median follow-up ( ~ 15 year ) OBJECTIFS Primary : â€¢ To compare incidence late cardiac event anthracycline non-anthracycline chemotherapy give node-positive breast cancer patient Belgian three arm randomize clinical trial Secondary : - To compare late incidence cardiac event higher low dose anthracycline treat node-positive breast cancer patient ; - To compare anthracyclines ( high low dos ) non-anthracycline chemotherapy : - leave ventricular diastolic function assess Echo - exercise capacity assess 6-minute walk test ( 6MWT ) - cardiac morphology ( myocardial inflammation injury , fibrosis , LVEF ) assess MRI - serum cardiac biomarkers ( BNP TNT ) - patient-reported cardiac symptom - patient-reported cardiac symptom assess QOL questionnaire associate subclinical finding LVEF assessment - cognitive function , functional autonomy , psychological distress</brief_summary>
	<brief_title>Late Cardiac Evaluation Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients</brief_title>
	<detailed_description>The primary objective study compare incidence cardiac event [ ( define asymptomatic systolic dysfunction ( LVEF &lt; 50 % , asymptomatic NYHA I ) symptomatic heart failure NYHA class II-IV either Echo and/or clinical exam ( LVEF &lt; 50 % heart failure symptom ) ] anthracycline non-anthracycline chemotherapy treat node-positive breast cancer patient long-term follow-up . We define binary status patient : cardiac event / one cardiac event . Analysis primary endpoint involve comparison CMF-treated patient versus pool anthracycline treat patient ( EC HEC ) . If significant difference detect , pair comparison also perform primary endpoint ( CMF versus EC , CMF versus HEC , EC versus HEC ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Alive , free recurrence , Not lose followup Last workup old 1 year exclude relapse . If old 1 year , new workup ( PE , blood test MMG ) perform prior entry study Patients previously diagnose CHF free recurrence also invited participate , contraindication Patients able perform prescribed assessment Death Breast cancer recurrence Unwilling perform exam per protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>CMF</keyword>
	<keyword>HEC</keyword>
	<keyword>EC</keyword>
	<keyword>node positive</keyword>
	<keyword>breast cancer</keyword>
</DOC>